Stephen Stahl, MD PhD
Department of Psychiatry, San Diego School of Medicine, University of California, San Diego, California; Psychopharmacology California Department of State Hospitals, California; University of Cambridge, Cambridge, United Kingdom
Original Research
Lumateperone as Adjunctive Therapy in MDD: A Randomized, Double-Blind, Phase 3 Trial
August 25, 2025
In patients with MDD with inadequate antidepressant response, adjunctive lumateperone 42 mg significantly improved depression symptoms and severity versus adjunctive placebo, and it was generally well tolerated.
